2025
Ultrasound Guidance for Botulinum Toxin Injection of Muscles Innervated by the Facial Nerve: A Systematic Review of Anatomical Precision, Safety, and Outcomes
Chowdhury R, Schiff B, Lee Y, Mohan S. Ultrasound Guidance for Botulinum Toxin Injection of Muscles Innervated by the Facial Nerve: A Systematic Review of Anatomical Precision, Safety, and Outcomes. Aesthetic Surgery Journal 2025, sjaf175. PMID: 40971765, DOI: 10.1093/asj/sjaf175.Peer-Reviewed Original ResearchUltrasound guidanceBotulinum toxin injectionSystematic reviewLandmark-based techniqueAdverse eventsPatient satisfactionPatient-reported measuresHigh-resolution ultrasoundOff-target deliveryBotulinum toxin type AInjection of muscleRisk of biasCadaveric trialsRandomized Controlled TrialsToxin type ARhytid reductionFacial nerveFacial synkinesisClinical efficacyClinical outcomesProspective cohortClinical studiesBoNT-AFacial symmetryInjection accuracy
2024
Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation
Piccini J, Ahlsson A, Dorian P, Gillinov A, Kowey P, Mack M, Milano C, Noiseux N, Perrault L, Ryan W, Steinberg J, Voisine P, Waldron N, Gleason K, Titanji W, Leaback R, O’Sullivan A, Ferguson W, Benussi S, Investigators N, Akhter S, Andreas M, Benussi S, Castella M, Dalrymple-Hay M, El-Eshmawi A, Groh M, Hanke T, Jeanmart H, Katz M, McCullough J, Melby S, Miller J, Noiseux N, Romano M, Perrault L, Piccini J, Podgoreanu M, Ryan W, Sharma V, Shults C, Teman N, Voisine P, Whitson B, Wickbom A, Vallabhajosyula P, Yau T. Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation. JACC Clinical Electrophysiology 2024, 10: 930-940. PMID: 38661602, DOI: 10.1016/j.jacep.2024.01.020.Peer-Reviewed Original ResearchPrevention of postoperative atrial fibrillationPostoperative atrial fibrillationCoronary Artery Bypass GraftingRate of postoperative atrial fibrillationSafety of botulinum toxin type ACardiac surgeryPrimary endpointBotulinum toxin type AToxin type AAtrial fibrillationAssociated with increased morbidityRate of adverse eventsDose-ranging studyPlacebo-controlled trialOpen-chest cardiac surgeryType of surgeryEpicardial fat padsInjection of botulinum toxinArtery Bypass GraftingRandomized clinical trialsPlacebo-ControlledValve surgeryDouble-blindPlacebo groupContinuous AF
2017
Progress on Botulinum Toxin Type A-Induced Pain Relief in the Field of Plastics
Lu X, Chen G, Ren P, Yang Y, Fan F. Progress on Botulinum Toxin Type A-Induced Pain Relief in the Field of Plastics. Journal Of Craniofacial Surgery 2017, 28: 2045-2052. PMID: 28938326, DOI: 10.1097/scs.0000000000003981.Peer-Reviewed Original ResearchConceptsBotulinum toxin type AToxin type APain alleviationBotulinum Toxin Type A InjectionsBTX-A injectionMain surgical procedureMajor adverse effectsFavorable side effectType AWeb of ScienceAnalgesic effectivenessInflammatory painNeuropathic painPain reliefPostoperative painA injectionAnalgesic mechanismsNociceptive painRetrospective cohortPostoperative rehabilitationPatient seriesClinical trialsInclusion criteriaSurgical proceduresPain
2016
Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials
Morra M, Elgebaly A, Elmaraezy A, Khalil A, Altibi A, Vu T, Mostafa M, Huy N, Hirayama K. Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials. The Journal Of Headache And Pain 2016, 17: 63. PMID: 27377706, PMCID: PMC4932020, DOI: 10.1186/s10194-016-0651-8.Peer-Reviewed Original ResearchConceptsRandomized Controlled TrialsTrigeminal neuralgiaBTX-AMeta-analysisSafety of BTX-AEfficacy of botulinum toxin type AMeta-analysis of randomized controlled trialsControlled TrialsSystematic reviewRecurrent pain attacksTreatment of TNPublished randomized controlled trialsNo significant heterogeneityBTX-A groupBotulinum toxin type ABotulinum Toxin A TherapyPain attacksTN patientsToxin type AA therapyClinical outcomesTreatment optionsTherapeutic efficacyQuality of lifeProportion of respondents
2015
Use of Clostridium botulinum toxin in gastrointestinal motility disorders in children
Arbizu RA, Rodriguez L. Use of Clostridium botulinum toxin in gastrointestinal motility disorders in children. World Journal Of Gastrointestinal Endoscopy 2015, 7: 433-437. PMID: 25992183, PMCID: PMC4436912, DOI: 10.4253/wjge.v7.i5.433.Commentaries, Editorials and LettersGastrointestinal motility disordersMotility disordersBotulinum toxin type APatients 12 yearsToxin type AExcessive neural activityTreatment of strabismusBotulinum neurotoxin type AType ANeurotoxin type ABowel perforationPresynaptic releaseTherapeutic applicationsClostridium botulinum toxinSignificant complicationsMinor painCentral originBotulinum toxinGastroenterological conditionsAllergic reactionsParalytic diseaseSignificant paralysisGastrointestinal tractObligate anaerobic bacteriaClinical experience
2007
Effect of Botulinum Toxin Type A on Tear Production After Treatment of Lateral Canthal Rhytids
Arat Y, Yen M. Effect of Botulinum Toxin Type A on Tear Production After Treatment of Lateral Canthal Rhytids. Ophthalmic Plastic And Reconstructive Surgery 2007, 23: 22-24. PMID: 17237684, DOI: 10.1097/iop.0b013e31802dfca7.Peer-Reviewed Original ResearchConceptsSchirmer test resultsLateral canthal rhytidsTear productionBotulinum toxin type ADry eyeToxin type ATreatment of lateral canthal rhytidsFollow-upSchirmer 1 testUnits of botulinum toxinDry-eye symptomsDecreased tear productionBotulinum toxinCrow's feet areasMonths follow-upBotulinum toxin type A injectionBotulinum toxin injectionEffect of botulinum toxin type ADry-eyeType ASchirmerPatientsToxin injectionCrow's-feetStatistical difference
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply